Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2375833 | 0.90 | CYP3A4 (0.53) | CYP3A4TSHRHPGDSMN1; SMN2LPAR3 | |
| SCHEMBL575735 | 0.84 | CYP3A4 (0.56) | CYP3A4TSHRHPGDSMN1; SMN2LPAR3 | |
| SCHEMBL5485187 | 0.84 | CYP3A4 (0.56) | CYP3A4TSHRHPGDSMN1; SMN2LPAR3 | |
| SCHEMBL28226198 | 0.82 | CYP3A4 (0.54) | CYP3A4TSHRHPGDSMN1; SMN2LPAR3 | |
| SCHEMBL575803 | 0.81 | CYP3A4 (0.64) | CYP3A4TSHRHPGDSMN1; SMN2LPAR3 | |
| Ether SCHEMBL28514521 | 0.80 | CYP3A4 (0.52) | CYP3A4TSHRHPGDSMN1; SMN2LPAR3 | |
| SCHEMBL27845160 | 0.80 | CYP3A4 (0.52) | CYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL16605635 | 0.80 | CYP3A4 (0.52) | CYP3A4TSHRHPGDSMN1; SMN2LPAR3 | |
| SCHEMBL2171452 | 0.78 | CYP3A4 (0.50) | CYP3A4TSHRHPGDSMN1; SMN2LPAR3 | |
| SCHEMBL1359596 | 0.78 | CYP3A4 (0.50) | CYP3A4TSHRHPGDSMN1; SMN2LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987489-B2 | Method for producing mono-carboxy-functionalized dialkylphosphinic acids, esters and salts using a vinyl ether and the use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-03-24 | — | — | US | disclosed |
| EP-2373669-B1 | METHOD FOR PRODUCING MONO-CARBOXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS AND SALTS USING A VINYL ETHER AND THE USE THEREOF | CLARIANT FINANCE BVI LTD (VG) | 2013-09-11 | — | — | EP | disclosed |
| US-20110275744-A1 | Method for Producing Mono-Carboxy-Functionalized Dialkylphosphinic Acids, Esters and Salts Using a Vinyl Ether and the Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-11-10 | — | — | US | disclosed |
| EP-2373669-A1 | METHOD FOR PRODUCING MONO-CARBOXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS AND SALTS USING A VINYL ETHER AND THE USE THEREOF | Clariant International Ltd. (CH) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010063344-A1 | METHOD FOR PRODUCING MONO-CARBOXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS AND SALTS USING A VINYL ETHER AND THE USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275744-A1 | Method for Producing Mono-Carboxy-Functionalized Dialkylphosphinic Acids, Esters and Salts Using a Vinyl Ether and the Use Thereof | SCO2, HAO2, ACSL3 | CYP3A4 1120/4885TSHR 1785/4885HPGD 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.